Approval · Notice of Compliance 23967 · 2020
M-AZITHROMYCIN: Notice of Compliance 23967
Issued July 28, 2020
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 23967
- Date
- July 28, 2020
- Company
- Mantra Pharma Inc.Brossard, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Abbreviated New Drug Submission (ANDS)
- Submission class
- Admin
- Reason
- Administrative: Licensing Agreement Between TwoCompanies
- Canadian reference product
- ZITHROMAX (Pfizer Canada Ulc)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| M-AZITHROMYCIN | 02502038 | Marketed |
| M-AZITHROMYCIN | 02502046 | Approved |
Medicinal ingredients
- AZITHROMYCIN DIHYDRATE 250 MG per TAB
- AZITHROMYCIN DIHYDRATE 600 MG per TAB